News & Updates

In patients with double-hit lymphoma (DHL), the addition of the BCL2 inhibitor venetoclax to a chemoimmunotherapeutic regimen comprising DA-EPOCH-R* led to excess treatment-related mortality compared with DA-EPOCH-R alone, according to the initial results of the phase II/III Alliance A051701 trial.

Treatment with 42-mg lumateperone daily leads to significant improvement in depression symptoms, with no serious safety issues, among patients with major depressive episodes associated with both bipolar I and II disorders, a study has shown.

For older acute coronary syndrome (ACS) patients with implanted bioabsorbable polymer sirolimus-eluting stents, a strategy involving ticagrelor monotherapy after 3‐month dual antiplatelet therapy (DAPT) is better than ticagrelor‐based 12‐month DAPT, according to a post hoc analysis of the TICO* trial. Furthermore, the beneficial effect of ticagrelor monotherapy increases with age and is strongest among patients aged ≥64 years.

Treatment with apremilast appears safe and effective against mild to moderate plaque psoriasis, according to a recent study.

The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.

Patients with hyperlipidemia who take their statin medication as prescribed appear to do well, with treatment adherence conferring significant protection against the risk of ischaemic and haemorrhagic strokes, as reported in a study.